Seroprevalence of Cytomegalovirus Antibodies Among COVID-19 Patients
Mohamed N. Ibrahim 1,2
1Clinical Laboratories department, College of Applied Medical Sciences, Jouf University, Qurayat, Saudi Arabia
2 Microbiology department, Faculty of Science, Ain Shams University, Egypt
Corresponding Author E-mail: mnabil@ju.,edu.sa
Abstract: One of the biggest infectious diseases for humans in modern history is the COVID-19 pandemic. The disease mechanisms of human viral infections have been modified by virus-virus interaction. This study was carried out to detect the seroprevalence of CMV in COVID-19 patients. A total of 105 cases (58 females and 47 males) with an age range of 17-65 years (mean age 39.52±11.02 years) were included in this study. HCMV-IgG and IgM were determined in subjects' cases. Sixty-five out of 105 (62%) were positive for SARS-CoV-2, while 40 (38%) had negative SARS-CoV-2. Forty-seven (72.3%) and 11 (16.9%) cases out of 65 SARS-CoV-2 positive patients were positive for CMV-IgG and IgM antibodies, respectively. No significant differences were noted between females and males in terms of seroprevalence rates. A high rate of positive CMV-IgG was observed among 40-64 years COVID-19 patients. It is concluded that the seroprevalence of CMV antibodies amongst COVID-19 cases is high in relation to findings in cases without SARSCoV-2.
Keywords: COVID-19; Cytomegalovirus; CMV-IgG; CMV- IgM; SARS-CoV-2 Back to TOC